EGFR‐tyrosine kinase inhibitor (TKI) showed higher objective response rates and progression‐free survival when used in the treatment of advanced NSCLC patients compared to traditional cytotoxic therapy.26 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.